Intest Res.  2014 Apr;12(2):103-109. 10.5217/ir.2014.12.2.103.

Natural Product-Derived Drugs for the Treatment of Inflammatory Bowel Diseases

• Joo YE

• KMID: 2284894
• DOI: http://doi.org/10.5217/ir.2014.12.2.103

Abstract

Natural products have been used as drugs for millennia, and the therapeutic potential of natural products has been studied for more than a century. Since the mid-1880s, approximately 60% of drugs have originated from natural products. Recently, the importance of using natural products has increased, as has interest in discovering efficient new drugs. Natural drugs are desirable for the treatment of inflammatory bowel diseases, such as ulcerative colitis and Crohn's disease. This review discusses the discovery and development of drugs derived from natural products for the treatment of inflammatory bowel diseases.

Keyword

Natural product; Drug discovery; Inflammatory bowel disease

MeSH Terms

Biological Products
Colitis, Ulcerative
Crohn Disease
Drug Discovery
Inflammatory Bowel Diseases*
Biological Products

Figure

• 

  Fig. 1 Schematic of the process of drug discovery from natural products.

Reference

1. Cassebaum H. News of the discovery of acids in organic material by C.W. Scheele (author's transl). Pharmazie. 1981; 36:135–138. PMID: 7015369.

2. Hamilton GR, Baskett TF. In the arms of Morpheus the development of morphine for postoperative pain relief. Can J Anaesth. 2000; 47:367–374. PMID: 10764185.

3. Newman DJ, Cragg GM, Snader KM. Natural products as sources of new drugs over the period 1981-2002. J Nat Prod. 2003; 66:1022–1037. PMID: 12880330.

4. Itokawa H, Morris-Natschke SL, Akiyama T, Lee KH. Plant-derived natural product research aimed at new drug discovery. J Nat Med. 2008; 62:263–280. PMID: 18425692.

5. Hur SJ, Kang SH, Jung HS, et al. Review of natural products actions on cytokines in inflammatory bowel disease. Nutr Res. 2012; 32:801–816. PMID: 23176791.

6. Ng SC, Lam YT, Tsoi KK, Chan FK, Sung JJ, Wu JC. Systematic review: the efficacy of herbal therapy in inflammatory bowel disease. Aliment Pharmacol Ther. 2013; 38:854–863. PMID: 23981095.

7. Langmead L, Chitnis M, Rampton DS. Use of complementary therapies by patients with IBD may indicate psychosocial distress. Inflamm Bowel Dis. 2002; 8:174–179. PMID: 11979137.

8. Langmead L, Makins RJ, Rampton DS. Anti-inflammatory effects of aloe vera gel in human colorectal mucosa in vitro. Aliment Pharmacol Ther. 2004; 19:521–527. PMID: 14987320.

9. Dahmen U, Gu YL, Dirsch O, et al. Boswellic acid, a potent anti-inflammatory drug, inhibits rejection to the same extent as high dose steroids. Transplant Proc. 2001; 33:539–541. PMID: 11266947.

10. Gupta I, Parihar A, Malhotra P, et al. Effects of gum resin of Boswellia serrata in patients with chronic colitis. Planta Med. 2001; 67:391–395. PMID: 11488449.

11. Singh S, Khajuria A, Taneja SC, Johri RK, Singh J, Qazi GN. Boswellic acids: A leukotriene inhibitor also effective through topical application in inflammatory disorders. Phytomedicine. 2008; 15:400–407. PMID: 18222672.

12. Krieglstein CF, Anthoni C, Rijcken EJ, et al. Acetyl-11-keto-beta-boswellic acid, a constituent of a herbal medicine from Boswellia serrata resin, attenuates experimental ileitis. Int J Colorectal Dis. 2001; 16:88–95. PMID: 11355324.

13. Kudo T, Okamura S, Zhang Y, Masuo T, Mori M. Topical application of glycyrrhizin preparation ameliorates experimentally induced colitis in rats. World J Gastroenterol. 2011; 17:2223–2228. PMID: 21633533.

14. Yuan H, Ji WS, Wu KX, Jiao JX, Sun LH, Feng YT. Anti-inflammatory effect of Diammonium Glycyrrhizinate in a rat model of ulcerative colitis. World J Gastroenterol. 2006; 12:4578–4581. PMID: 16874877.

15. Langmead L, Dawson C, Hawkins C, Banna N, Loo S, Rampton DS. Antioxidant effects of herbal therapies used by patients with inflammatory bowel disease: an in vitro study. Aliment Pharmacol Ther. 2002; 16:197–205. PMID: 11860402.

16. Langmead L, Rampton DS. Review article: complementary and alternative therapies for inflammatory bowel disease. Aliment Pharmacol Ther. 2006; 23:341–349. PMID: 16422993.

17. Subbotina MD, Timchenko VN, Vorobyov MM, Konunova YS, Aleksandrovih YS, Shushunov S. Effect of oral administration of tormentil root extract (Potentilla tormentilla) on rotavirus diarrhea in children: a randomized, double blind, controlled trial. Pediatr Infect Dis J. 2003; 22:706–711. PMID: 12913771.

18. Huber R, Ditfurth AV, Amann F, et al. Tormentil for active ulcerative colitis: an open-label, dose-escalating study. J Clin Gastroenterol. 2007; 41:834–838. PMID: 17881930.

19. Ben-Arye E, Goldin E, Wengrower D, Stamper A, Kohn R, Berry E. Wheat grass juice in the treatment of active distal ulcerative colitis: a randomized double-blind placebo-controlled trial. Scand J Gastroenterol. 2002; 37:444–449. PMID: 11989836.

20. Ali T, Shakir F, Morton J. Curcumin and inflammatory bowel disease: biological mechanisms and clinical implication. Digestion. 2012; 85:249–255. PMID: 22950087.

21. Cuendet M, Pezzuto JM. The role of cyclooxygenase and lipoxygenase in cancer chemoprevention. Drug Metabol Drug Interact. 2000; 17:109–157. PMID: 11201293.

22. Holt PR, Katz S, Kirshoff R. Curcumin therapy in inflammatory bowel disease: a pilot study. Dig Dis Sci. 2005; 50:2191–2193. PMID: 16240238.

23. Hanai H, Iida T, Takeuchi K, et al. Curcumin maintenance therapy for ulcerative colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol Hepatol. 2006; 4:1502–1506. PMID: 17101300.

24. Lim BO. Coriolus versicolor suppresses inflammatory bowel disease by Inhibiting the expression of STAT1 and STAT6 associated with IFN-gamma and IL-4 expression. Phytother Res. 2011; 25:1257–1261. PMID: 21796702.

25. Wasser SP, Weis AL. Therapeutic effects of substances occurring in higher Basidiomycetes mushrooms: a modern perspective. Crit Rev Immunol. 1999; 19:65–96. PMID: 9987601.

26. Kim YO, Park HW, Kim JH, Lee JY, Moon SH, Shin CS. Anticancer effect and structural characterization of endo-polysaccharide from cultivated mycelia of Inonotus obliquus. Life Sci. 2006; 79:72–80. PMID: 16458328.

27. Mishra SK, Kang JH, Kim DK, Oh SH, Kim MK. Orally administered aqueous extract of Inonotus obliquus ameliorates acute inflammation in dextran sulfate sodium (DSS)-induced colitis in mice. J Ethnopharmacol. 2012; 143:524–532. PMID: 22819687.

28. Debnath T, Kim da H, Lim BO. Natural products as a source of anti-inflammatory agents associated with inflammatory bowel disease. Molecules. 2013; 18:7253–7270. PMID: 23783459.

29. Liu L, Yuan S, Sun Y, et al. The possible mechanisms of Fructus Mume pill in the treatment of colitis induced by 2,4,6-trinitrobenzene sulfonic acid in rats. J Ethnopharmacol. 2009; 126:557–564. PMID: 19703546.

30. Jin HL, Lee BR, Lim KJ, Debnath T, Shin HM, Lim BO. Anti-inflammatory effects of Prunus mume mixture in colitis induced by dextran sodium sulfate. Korean J Med Crop Sci. 2011; 19:16–23.

31. Chen Y, Zhang H, Li YX, et al. Crocin and geniposide profiles and radical scavenging activity of gardenia fruits (Gardenia jasminoides Ellis) from different cultivars and at the various stages of maturation. Fitoterapia. 2010; 81:269–273. PMID: 19815056.

32. Oh PS, Lim KT. Plant originated glycoprotein has anti-oxidative and anti-inflammatory effects on dextran sulfate sodium-induced colitis in mouse. J Biomed Sci. 2006; 13:549–560. PMID: 16586048.

33. Hsiang CY, Lo HY, Huang HC, Li CC, Wu SL, Ho TY. Ginger extract and zingerone ameliorated trinitrobenzene sulphonic acid-induced colitis in mice via modulation of nuclear factor-kappaB activity and interleukin-1beta signalling pathway. Food Chem. 2013; 136:170–177. PMID: 23017409.

34. dos Reis SB, de Oliveira CC, Acedo SC, et al. Attenuation of colitis injury in rats using Garcinia cambogia extract. Phytother Res. 2009; 23:324–329. PMID: 18979524.

35. Dryden GW, Song M, McClain C. Polyphenols and gastrointestinal diseases. Curr Opin Gastroenterol. 2006; 22:165–170. PMID: 16462174.

36. Yang F, Oz HS, Barve S, de Villiers WJ, McClain CJ, Varilek GW. The green tea polyphenol (-)-epigallocatechin-3-gallate blocks nuclear factor-kappa B activation by inhibiting I kappa B kinase activity in the intestinal epithelial cell line IEC-6. Mol Pharmacol. 2001; 60:528–533. PMID: 11502884.

37. Ran ZH, Chen C, Xiao SD. Epigallocatechin-3-gallate ameliorates rats colitis induced by acetic acid. Biomed Pharmacother. 2008; 62:189–196. PMID: 18325726.

38. Abboud PA, Hake PW, Burroughs TJ, et al. Therapeutic effect of epigallocatechin-3-gallate in a mouse model of colitis. Eur J Pharmacol. 2008; 579:411–417. PMID: 18022615.

39. Cruz T, Galvez J, Ocete MA, Crespo ME, Sanchez de Medina LHF, Zarzuelo A. Oral administration of rutoside can ameliorate inflammatory bowel disease in rats. Life Sci. 1998; 62:687–695. PMID: 9472728.

40. Galvez J, Cruz T, Crespo E, et al. Rutoside as mucosal protective in acetic acid-induced rat colitis. Planta Med. 1997; 63:409–414. PMID: 9342943.

41. Kwon KH, Murakami A, Tanaka T, Ohigashi H. Dietary rutin, but not its aglycone quercetin, ameliorates dextran sulfate sodium-induced experimental colitis in mice: attenuation of pro-inflammatory gene expression. Biochem Pharmacol. 2005; 69:395–406. PMID: 15652231.

42. Burke MD, Berger EM, Schreiber SL. A synthesis strategy yielding skeletally diverse small molecules combinatorially. J Am Chem Soc. 2004; 126:14095–14104. PMID: 15506774.

43. Balunas MJ, Kinghorn AD. Drug discovery from medicinal plants. Life Sci. 2005; 78:431–441. PMID: 16198377.

44. Mishra BB, Tiwari VK. Natural products: an evolving role in future drug discovery. Eur J Med Chem. 2011; 46:4769–4807. PMID: 21889825.

45. Michel T, Halabalaki M, Skaltsounis AL. New concepts, experimental approaches, and dereplication strategies for the discovery of novel phytoestrogens from natural sources. Planta Med. 2013; 79:514–532. PMID: 23479392.

46. Hsieh PW, Hung CF, Fang JY. Current prodrug design for drug discovery. Curr Pharm Des. 2009; 15:2236–2250. PMID: 19601825.

47. Reichert JM. Trends in development and approval times for new therapeutics in the United States. Nat Rev Drug Discov. 2003; 2:695–702. PMID: 12951576.

48. Descotes J. Immunotoxicology: role in the safety assessment of drugs. Drug Saf. 2005; 28:127–136. PMID: 15691223.

49. Potterat O, Hamburger M. Drug discovery and development with plant-derived compounds. Prog Drug Res. 2008; 65:4547–118. PMID: 18084913.

50. Dickson M, Gagnon JP. Key factors in the rising cost of new drug discovery and development. Nat Rev Drug Discov. 2004; 3:417–429. PMID: 15136789.